TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04454918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Oral Capsule
Description: TAK-906 capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-906 Intravenous Infusion
Description: \[14C\]-TAK-906 intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-TAK-906 Oral Solution
Description: \[14C\]-TAK-906 oral solution.
Study: NCT04055077

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA I
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA II
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-flow nasal oxygenation (LFNO) ASA III
Description: Active comparator LFNO: O2 flow 5 L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASA I
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASAII
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation (HFNO) ASA III
Description: Experimental HFNO: O2 flow 40 L/min, FiO2 40%
Study: NCT00624598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMART
Description: Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
Study: NCT02630615

Intervention type: OTHER
Intervention: Blood draw
Description: Whole blood will be collected using standard phlebotomy procedures

Intervention type: OTHER
Intervention: Blood draw
Description: Whole blood will be collected using standard phlebotomy procedures
Study: NCT02324101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hsp90
Description: Detect plasma Hsp90α concentration
Study: NCT00840112

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E supplement
Description: 400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
Study: NCT03822845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-HBED-CC PET
Description: Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Study: NCT03216226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon Analog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: Native Glucagon
Study: NCT01574469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)
Description: 1 = Intervention 1 (2 test products / day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Low fat fermented dairy product (control)
Description: 2 = Intervention 2 (2 control products/day)
Study: NCT01213628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: humidified warmed CO2
Description: Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
Study: NCT02557139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil Capsule
Study: NCT04058964

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Hyaluronidase PH20
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01287702

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Delayed feeding
Description: patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dealyed feeding
Description: patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early feeding
Description: patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
Study: NCT04569565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX catheter
Description: Placement of PleurX catheter for refractory cirrhotic ascites, with follow up monitoring
Study: NCT02503761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem.
Description: Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem.
Description: Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
Study: NCT04668755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Charcot Restraint Orthotic Walker 3d printed sole
Description: The Charcot Restraint Orthotic Walker (CROW) consists of anterior and posterior shells creating a total contact environment based on a rocker sole. the sole is manufactured by 3d printed Metamaterial .~Manufacture of the 3d printed sole of the CROW paths through two stages ;Computer aided designing (CAD) and computer aided manufacturing (CAM) .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Generic Charcot Restraint orthotic walker
Description: It is a clamshell (two piece) design that provides complete/total contact over the shin, calf and foot. The CROW reduces all motion in the ankle and foot to reduce potential for further injury. It is fully padded on the inside, and the bottom is covered with a material similar to shoe soling. It is not worn with a shoe.
Study: NCT01519921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
Study: NCT03327207

Intervention type: OTHER
Intervention: Non Interventional
Description: Non Interventional

Intervention type: OTHER
Intervention: Non Interventional
Description: Non Interventional
Study: NCT02382432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine 0.4mg/kg
Description: 2ml intravenous bolus slowly injected in 2minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2ml intravenous bolus slowly injected in 2minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2ml intravenous bolus slowly injected in 2minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2ml intravenous bolus slowly injected in 2minutes
Study: NCT00588107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Intervention
Description: Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: print materials
Description: tailored print materials designed to aid in smoking reduction and cessation
Study: NCT02289157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Description: Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
Study: NCT02902562

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Contrast Enhanced Ultrasound (CEUS)
Description: An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
Study: NCT01523106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: dietary supplement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
Study: NCT01588730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially Available Static Night splint
Description: A commericially avilable static night splint will be worn for 4-6 hours during rest.
Study: NCT02416206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: BeEAM
Study: NCT03177655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided Imagery meditation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Journaling
Description: Keeping a journal
Study: NCT05633758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of administration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of administration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
Study: NCT00843219

Intervention type: PROCEDURE
Intervention: PET/CT Scan
Description: PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
Study: NCT02846025

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and capsule of oil hazel
Description: rich diet aministracao folate and capsule of oil hazel

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and capsule of oil hazel
Description: rich diet aministracao folate and capsule of oil hazel

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and placebo
Description: rich diet aministracao folate and placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folate and placebo
Description: rich diet aministracao folate and placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: antioxidant and placebo
Description: antioxidant diet (90μg folate) and placebo capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: antioxidant and placebo
Description: antioxidant diet (90μg folate) and placebo capsule
Study: NCT01666028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlorenceD or similar closed loop glucose control system
Description: Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CSII with real-time CGM
Description: Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
Study: NCT01656408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8150
Study: NCT01538095

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT00232752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4.0 CYPHER Sirolimus-Eluting Coronary Stent
Description: 4.0 CYPHER Sirolimus-Eluting Coronary Stent
Study: NCT03088956

Intervention type: OTHER
Intervention: Assessments
Description: Cognitive, Behavioral and Functional as described in the Outcome Measures

Intervention type: OTHER
Intervention: Assessments
Description: Cognitive, Behavioral and Functional as described in the Outcome Measures
Study: NCT04459650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma system
Description: Participants will receive PRP obtained with PRP harvesting kits on one side of the scalp and no injections on the other side of the scalp (split-scalp technique). The entire half of the intended scalp will receive inter-follicular injections of PRP under aseptic conditions at the amount of 0.05-0.1 ml/cm2 in a retrograde fashion from deep to superficial, at every centimeter throughout the treated site. For study purposes, Study Day 0 is defined as the first day of injection. Subsequently the patient will continue therapy every 4 weeks for a total of 3 injections (12 weeks).
Study: NCT02869464

Intervention type: OTHER
Intervention: Imaging-Ultrasound
Description: Abdominal Ultrasound

Intervention type: OTHER
Intervention: Imaging-MRA
Description: Non-contrast Enhanced Magnetic Resonance Angiogram

Intervention type: GENETIC
Intervention: DNA, RNA testing
Description: To test for the co-prevalence of shared genetic markers in afflicted populations.

Intervention type: GENETIC
Intervention: DNA, RNA testing
Description: To test for the co-prevalence of shared genetic markers in afflicted populations.
Study: NCT01721044

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Participants will continue to take background cDMARD therapy throughout study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Participants will continue to take background cDMARD therapy throughout study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cDMARD
Description: Participants will continue to take background cDMARD therapy throughout study.
Study: NCT01623453

Intervention type: BIOLOGICAL
Intervention: Autologous adipose derived stem cells(low dose group)
Description: low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.

Intervention type: BIOLOGICAL
Intervention: Autologous adipose derived stem cells(high dose group)
Description: high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
Study: NCT02436629

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich concentrated beetroot juice
Description: James White, Beet It Sport Shot, 70ml (Standard)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted concentrated red beetroot juice
Description: Beet It Sport Shot, 70ml (Placebo)
Study: NCT01434199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UPD guidance
Description: A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
Study: NCT00612144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin fixed combination
Description: Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl
Description: Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG
Study: NCT01523912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of dysplastic mucosa (HALO)
Description: Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
Study: NCT00997308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral, for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Solution, oral, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01621269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Study: NCT03483857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
Study: NCT02039141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Every Little Step Counts Intervention
Description: Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc.